Mohamed Dewji's Linkedin Analytics

Over the course of his career to date, Mohamed (Raz) has held roles of increasing seniority and made significant leadership contributions to six oncology drug approvals and launches for various cancer treatment settings: Taxol [Bristol-Myers Squibb]; Amifostine [US Bioscience]; Sunitinib & Axitinib [Pfizer Oncology]; Pazopanib [GSK Oncology]; Osimertinib [AstraZeneca Oncology]. Mohamed currently works as a global pharmaceutical consultant within the oncology therapeutic area [mrdpharma.com] Summary of Relevant Experience:  More than 30 years of international pharmaceutical industry expertise in oncology clinical development and global medical affairs  Strategic development and trial design & execution across all phases of oncology drug development, taking molecules from first in human to registration and Phase IV (experience includes taxanes, monoclonal antibodies, novel biologics, TKIs’ and cytoprotective agents)  Management of global clinical trials in lung, breast; genitourinary; gastrointestinal and other solid tumours  Broad oncology experience, in both exploratory and late-stage clinical development within large and speciality pharma companies and global medical affairs activities spanning all international markets (including Japan, and Asia / Pacific region).  Global team leadership within a highly matrixed environment. Mohamed is a highly experienced and talented oncology professional with broad strategic, development and regulatory expertise that spans across clinical development and medical affairs (including ‘real-world evidence’ and medical education). He has extensive global experience working for European and US-headquartered biopharmaceutical companies. Past pharma employers: Celltech Limited; BMS International (Brussels); US Bioscience (Philadelphia); Agouron Pharmaceuticals Inc (San Diego); Pfizer Oncology (Sandwich & Milano); GSK Oncology (Brentford UK); AstraZeneca Oncology (Cambridge UK).